Association of Clonal Hematopoiesis of Indeterminate Potential with Time to First Treatment, Incidence of Richter's Syndrome, and Overall Survival in Patients with Chronic Lymphocytic Leukemia

被引：0
|
作者：
Vijenthira, Abi [1 ,2 ]
Sekar, Aswin [3 ]
Gibson, Christopher J. [4 ,5 ]
Martindale, Stephen P. [3 ]
Fardoun, Rayan [3 ]
Tyekucheva, Svitlana [6 ]
Ren, Yue [7 ]
Fernandes, Stacey M. [3 ]
Knisbacher, Binyamin A. [8 ]
Hahn, Cynthia K. [3 ,8 ]
Getz, Gad [5 ,9 ,10 ]
Wu, Catherine J. [11 ,12 ,13 ]
Davids, Matthew S. [11 ,12 ,13 ]
Brown, Jennifer R. [13 ,14 ]
机构：
[1] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
[3] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Harvard Med Sch, Dept Med, Boston, MA 02115 USA
[6] Harvard TH Chan Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA USA
[7] Dana Farber Canc Inst, Dept Data Sci, Boston, MA 02115 USA
[8] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA
[9] Broad Inst MIT & Harvard, Canc Program, Cambridge, MA 02142 USA
[10] Massachusetts Gen Hosp, Dept Pathol, Canc Ctr, Boston, MA 02114 USA
[11] Dana Farber Boston Childrens Canc & Blood Disorde, Dept Med Oncol, Boston, MA USA
[12] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA
[13] Harvard Med Sch, Boston, MA 02115 USA
[14] Dana Farber Canc Inst, Dept Med Oncol, Newton, MA USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-163273
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：9868 / 9870
页数：3
相关论文
共 50 条
  • [41] Tumor Lysis Syndrome Caused by Unrecognized Richter's Transformation of Chronic Lymphocytic Leukemia: Treatment With Venetoclax for Suspected Disease Progression
    Azanza, Juan Jose Chango
    Sarmiento, Paola Michelle Calle
    Thomas, Vinay Mathew
    Lia, Nerea Lopetegui
    Kidwai, Neiha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (05)
  • [42] Richter's Syndrome In Chronic Lymphocytic Leukemia: Clinical and Laboratory Features In 119 Patients, Attempting To Identify Possible Risk Factors
    Tadmor, Tamar
    Fineman, Riva
    Shvidel, Lev
    Bairey, Osnat
    Goldschmidt, Neta
    Ruchlemer, Rosa
    Rachimi, Naomi Rahimi
    Herishanu, Yair
    Yuklea, Mona
    Arad, Ariela
    Aviv, Ariel
    Polliack, Aaron
    BLOOD, 2013, 122 (21)
  • [43] Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib
    Jacobs, Ryan
    Lu, Xiaoxiao
    Emond, Bruno
    Morrison, Laura
    Kinkead, Frederic
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Khan, Wasiulla
    Wu, Linda H.
    Qureshi, Zaina P.
    Levy, Moshe Yair
    FUTURE ONCOLOGY, 2024, 20 (01) : 39 - 53
  • [44] External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia
    Molica, Stefano
    Giannarelli, Diana
    Gentile, Massimo
    Cutrona, Giovanna
    Di Renzo, Nicola
    Di Raimondo, Francesco
    Neri, Antonino
    Federico, Massimo
    Ferrrarini, Manlio
    Morabito, Fortunato
    CANCER, 2013, 119 (06) : 1177 - 1185
  • [45] Soluble Cd52 levels predict time to first treatment for patients with chronic lymphocytic leukemia
    Vojdeman, Fie Juhl
    Kirkby, Nikolai
    Herman, Sarah E. M.
    Wiestner, Adrian
    Veer, Mars B. van T.
    Tjonnfjord, Geir
    Remes, Maija I.
    Kimby, Eva
    Polliack, Aaron
    Wu, Ka L.
    Doorduijn, Jeanette
    Alemayehu, Wendimagegn G.
    Wittebol, Shulamiet
    Kozak, Tomas
    Walewski, Jan
    Abrahamse-Testroote, Martine C. J.
    van Oers, Marinus H. J.
    Niemann, Carsten U.
    Geisler, Christian H.
    LEUKEMIA & LYMPHOMA, 2015, 56 : 134 - 136
  • [46] Development of a Novel Prognostic Scoring System of Time to First Treatment for Chinese Patients with Chronic Lymphocytic Leukemia
    Li, Heng
    Xiong, Wenjie
    Li, Zengjun
    Li, Shuhua
    Lv, Rui
    Zou, Dehui
    Qiu, Lugui
    BLOOD, 2016, 128 (22)
  • [47] Association of HLA-G Haplotype Risk Model with Treatment Free Survival In Chronic Lymphocytic Leukemia Patients
    Kapp, Johanna
    Ochsenfarth, Crista
    Switala, Magdalena
    Frey, Ulrich
    Sellmann, Ludger
    Duerig, Jan
    Horn, Peter A.
    Duehrsen, Ulrich
    Rebmann, Vera
    Nuckel, Holger
    BLOOD, 2010, 116 (21) : 1002 - 1003
  • [48] Association of HLA-G haplotype risk model with treatment free survival in chronic lymphocytic leukemia patients
    Kapp, J.
    Ochsenfarth, C.
    Switala, M.
    Frey, U.
    Sellmann, L.
    Duerig, J.
    Horn, P.
    Duehrsen, U.
    Rebmann, V
    Nueckel, H.
    ONKOLOGIE, 2010, 33 : 45 - 45
  • [49] Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection
    Bantilan, Kurt S.
    Kay, Neil E.
    Parikh, Sameer A.
    Rabe, Kari G.
    Call, Timothy G.
    Leis, Jose F.
    Ding, Wei
    Slager, Susan L.
    Soumerai, Jacob D.
    Roeker, Lindsey E.
    Mato, Anthony
    Zelenetz, Andrew D.
    LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 300 - 311
  • [50] PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA - CLINICAL BENEFITS OF ACHIEVING A DEEP RESPONSE TO FIRST-LINE THERAPY
    Samp, J.
    Guerin, A.
    Foster, R.
    Meissner, B.
    Rokito, A.
    Enschede, S. H.
    Gauthier, G.
    HAEMATOLOGICA, 2017, 102 : 718 - 719
12345